|
|
|
|
|
|
|
02.07.25 - 01:57
|
Granting of Stock Options and Vesting of Restricted Share Units (GlobeNewswire EN)
|
|
|
In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company's Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.06.25 - 10:03
|
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic....
|
|
|
25.06.25 - 10:03
|
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic....
|
|
|
25.06.25 - 09:06
|
DAX legt zu – Airbus, Befesa, Conti, DHL, Formycon, Nordex, Stratec, VW im Check (Der Aktionaer)
|
|
|
Die von Trump ausgerufene Waffenruhe im Nahen Osten hat an den internationalen Aktienmärkten für starke Kursgewinne gesorgt. Der DAX legte am Dienstag 372 Zähler oder 1,6 Prozent auf 23.641 zu. Auch am Mittwoch dominieren zum Handelsauftakt grüne Vorzeichen, wobei Airbus, Befesa, Conti, DHL, Formycon, Nordex, Stratec und VW im Fokus stehen....
|
|
|
23.06.25 - 10:03
|
European Medicines Agency Recommends Market Approval of AVT06, Alvotech′s Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein....
|
|
|
23.06.25 - 10:03
|
European Medicines Agency Recommends Market Approval of AVT06, Alvotech′s Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein....
|
|
|
11.06.25 - 22:24
|
Alvotech′s Private Placement Completed with Delivery of SDRs and Shares to Investors (GlobeNewswire EN)
|
|
|
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech....
|
|
|
11.06.25 - 22:21
|
Alvotech′s Private Placement Completed with Delivery of SDRs and Shares to Investors (GlobeNewswire EN)
|
|
|
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech....
|
|
|
|
|
06.06.25 - 14:33
|
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami (GlobeNewswire EN)
|
|
|
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST)....
|
|
|
06.06.25 - 14:33
|
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, June 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST)....
|
|
|
06.06.25 - 14:00
|
Alvotech and Dr. Reddy’s partner for Keytruda biosimilar (PBR)
|
|
|
The alliance leverages both companies' experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product's availability worldwide.
The post Alvotech and Dr. Reddy's partner for Keytruda biosimilar appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
